Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Declines By 11.0%

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 356,500 shares, a decrease of 11.0% from the December 15th total of 400,500 shares. Based on an average trading volume of 165,700 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a research note on Monday, January 6th.

Hedge Funds Weigh In On Immix Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of IMMX. Invst LLC purchased a new position in Immix Biopharma in the 2nd quarter worth approximately $57,000. FNY Investment Advisers LLC acquired a new position in shares of Immix Biopharma in the 4th quarter valued at approximately $63,000. Finally, Geode Capital Management LLC raised its position in shares of Immix Biopharma by 5.6% in the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock valued at $224,000 after purchasing an additional 7,954 shares in the last quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Shares of NASDAQ:IMMX traded down $0.02 during trading on Friday, reaching $2.04. 121,030 shares of the stock were exchanged, compared to its average volume of 140,296. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $5.73. The firm has a market cap of $56.12 million, a price-to-earnings ratio of -2.40 and a beta of 0.27. The firm’s 50-day moving average price is $2.07 and its 200 day moving average price is $1.95.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). As a group, equities research analysts forecast that Immix Biopharma will post -0.74 EPS for the current year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.